Avandamet

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

下载 资料单张 (PIL)
08-06-2016
下载 产品特点 (SPC)
08-06-2016
下载 公众评估报告 (PAR)
08-06-2016

有效成分:

rosiglitazone, metformin hydrochloride

可用日期:

SmithKline Beecham Plc

ATC代码:

A10BD03

INN(国际名称):

rosiglitazone, metformin

治疗组:

Drugs used in diabetes

治疗领域:

Diabetes Mellitus, Type 2

疗效迹象:

AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

產品總結:

Revision: 16

授权状态:

Withdrawn

授权日期:

2003-10-20

资料单张

                                Medicinal product no longer authorised
105
B. PACKAGE LEAFLET
Medicinal product no longer authorised
106
PACKAGE LEAFLET: INFORMATION FOR THE USER
AVANDAMET 1 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/1000 MG FILM-COATED TABLETS
AVANDAMET 4 MG/1000 MG FILM-COATED TABLETS
rosiglitazone/metformin HCl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
-
KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their symptoms are the same as yours.
-
IF ANY OF THE SIDE EFFECTS GETS SERIOUS, OR IF YOU NOTICE ANY SIDE
EFFECTS NOT LISTED IN THIS
LEAFLET, TELL YOUR DOCTOR OR PHARMACIST.
IN THIS LEAFLET
:
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
2.
BEFORE YOU TAKE AVANDAMET
3.
HOW TO TAKE AVANDAMET
4.
POSSIBLE SIDE EFFECTS
5
HOW TO STORE AVANDAMET
6.
FURTHER INFORMATION
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
AVANDAMET TABLETS ARE A COMBINATION OF TWO DIFFERENT MEDICINES
called
_rosiglitazone_
and
_metformin. _
These two medicines are used to treat
TYPE 2 DIABETES.
People with type 2 diabetes either don’t make enough insulin (a
hormone that controls blood sugar
levels), or don’t respond normally to the insulin their body makes.
Rosiglitazone and metformin work
together so your body makes better use of the insulin it produces, and
this helps reduce your blood
sugar to a normal level. Avandamet can be used alone or with a
sulphonylurea, another medicine for
diabetes.
2.
BEFORE YOU TAKE AVANDAMET
To help manage your diabetes, it is important that you follow any diet
and lifestyle advice from your
doctor as well as taking Avandamet.
DON’T TAKE AVANDAMET:
•
IF YOU ARE ALLERGIC
(
_hypersensitive_
) to rosiglitazone or metformin or any of the other
ingredients of Avandamet (
_listed in Section 6)_
•
IF YOU HAVE HAD A HEART ATTACK OR SEVERE ANGINA,
that’s being treated in hospital
•

                                
                                阅读完整的文件
                                
                            

产品特点

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
AVANDAMET 1 mg/500 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each tablet contains 1 mg of rosiglitazone (as rosiglitazone maleate)
and 500 mg of metformin
hydrochloride (corresponding to metformin free base 390 mg).
Excipients:
Each tablet contains lactose (approximately 6 mg).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Yellow film-coated tablets marked "gsk" on one side and "1/500" on the
other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
AVANDAMET is indicated in the treatment of type 2 diabetes mellitus
patients, particularly
overweight patients:
-
who are unable to achieve sufficient glycaemic control at their
maximally tolerated dose of oral
metformin alone.
-
in triple oral therapy with sulphonylurea in patients with
insufficient glycaemic control despite
dual oral therapy with their maximally tolerated dose of metformin and
a sulphonylurea (see
section 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The usual starting dose of AVANDAMET is 4 mg/day rosiglitazone plus
2000 mg/day metformin
hydrochloride.
Rosiglitazone can be increased to 8 mg/day after 8 weeks if greater
glycaemic control is required. The
maximum recommended daily dose of AVANDAMET is 8 mg rosiglitazone plus
2000 mg metformin
hydrochloride.
The total daily dose of AVANDAMET should be given in two divided
doses.
Dose titration with rosiglitazone (added to the optimal dose of
metformin) may be considered before
the patient is switched to AVANDAMET.
When clinically appropriate, direct change from metformin monotherapy
to AVANDAMET may be
considered.
Taking AVANDAMET with or just after food may reduce gastrointestinal
symptoms associated with
metformin.
Triple oral therapy (rosiglitazone, metformin and sulphonylurea) (see
section 4.4)
Medicinal product no longer authorised
3
-
Patients on metformin and sulp
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 08-06-2016
产品特点 产品特点 保加利亚文 08-06-2016
公众评估报告 公众评估报告 保加利亚文 08-06-2016
资料单张 资料单张 西班牙文 08-06-2016
产品特点 产品特点 西班牙文 08-06-2016
公众评估报告 公众评估报告 西班牙文 08-06-2016
资料单张 资料单张 捷克文 08-06-2016
产品特点 产品特点 捷克文 08-06-2016
公众评估报告 公众评估报告 捷克文 08-06-2016
资料单张 资料单张 丹麦文 08-06-2016
产品特点 产品特点 丹麦文 08-06-2016
公众评估报告 公众评估报告 丹麦文 08-06-2016
资料单张 资料单张 德文 08-06-2016
产品特点 产品特点 德文 08-06-2016
公众评估报告 公众评估报告 德文 08-06-2016
资料单张 资料单张 爱沙尼亚文 08-06-2016
产品特点 产品特点 爱沙尼亚文 08-06-2016
公众评估报告 公众评估报告 爱沙尼亚文 08-06-2016
资料单张 资料单张 希腊文 08-06-2016
产品特点 产品特点 希腊文 08-06-2016
公众评估报告 公众评估报告 希腊文 08-06-2016
资料单张 资料单张 法文 08-06-2016
产品特点 产品特点 法文 08-06-2016
公众评估报告 公众评估报告 法文 08-06-2016
资料单张 资料单张 意大利文 08-06-2016
产品特点 产品特点 意大利文 08-06-2016
公众评估报告 公众评估报告 意大利文 08-06-2016
资料单张 资料单张 拉脱维亚文 08-06-2016
产品特点 产品特点 拉脱维亚文 08-06-2016
公众评估报告 公众评估报告 拉脱维亚文 08-06-2016
资料单张 资料单张 立陶宛文 08-06-2016
产品特点 产品特点 立陶宛文 08-06-2016
公众评估报告 公众评估报告 立陶宛文 08-06-2016
资料单张 资料单张 匈牙利文 08-06-2016
产品特点 产品特点 匈牙利文 08-06-2016
公众评估报告 公众评估报告 匈牙利文 08-06-2016
资料单张 资料单张 马耳他文 08-06-2016
产品特点 产品特点 马耳他文 08-06-2016
公众评估报告 公众评估报告 马耳他文 08-06-2016
资料单张 资料单张 荷兰文 08-06-2016
产品特点 产品特点 荷兰文 08-06-2016
公众评估报告 公众评估报告 荷兰文 08-06-2016
资料单张 资料单张 波兰文 08-06-2016
产品特点 产品特点 波兰文 08-06-2016
公众评估报告 公众评估报告 波兰文 08-06-2016
资料单张 资料单张 葡萄牙文 08-06-2016
产品特点 产品特点 葡萄牙文 08-06-2016
公众评估报告 公众评估报告 葡萄牙文 08-06-2016
资料单张 资料单张 罗马尼亚文 08-06-2016
产品特点 产品特点 罗马尼亚文 08-06-2016
公众评估报告 公众评估报告 罗马尼亚文 08-06-2016
资料单张 资料单张 斯洛伐克文 08-06-2016
产品特点 产品特点 斯洛伐克文 08-06-2016
公众评估报告 公众评估报告 斯洛伐克文 08-06-2016
资料单张 资料单张 斯洛文尼亚文 08-06-2016
产品特点 产品特点 斯洛文尼亚文 08-06-2016
公众评估报告 公众评估报告 斯洛文尼亚文 08-06-2016
资料单张 资料单张 芬兰文 08-06-2016
产品特点 产品特点 芬兰文 08-06-2016
公众评估报告 公众评估报告 芬兰文 08-06-2016
资料单张 资料单张 瑞典文 08-06-2016
产品特点 产品特点 瑞典文 08-06-2016
公众评估报告 公众评估报告 瑞典文 08-06-2016

查看文件历史